Topics:

Gastrointestinal Cancer

Gastrointestinal Cancer

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

The CONCUR trial found that regorafenib improved overall survival in a large group of Asian patients with treatment-refractory metastatic colorectal cancer.

A 59-year-old man with metastatic gastric cancer presented to the oncology clinic with a 1-week history of positional headache, nausea, and vomiting. He stated that the headache was located in the frontal region, was 8 on a scale of 10 in intensity.

TAS-102, an oral combination of trifluridine and tipiracil hydrochloride, improved median overall survival in patients with refractory colorectal cancer.

Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

In this video from the 2015 ONS meeting, Dr. Omran discusses the high-risk of colorectal cancer among the Jordanian population and the need to promote more screening awareness.

Pages

Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.